Drug Profile
Research programme: JAK 1 inhibitors - AbbVie
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator AbbVie
- Class Anti-inflammatories
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sjogren's syndrome; Systemic lupus erythematosus
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Sjogren's-syndrome in USA
- 28 Dec 2021 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA
- 03 Nov 2017 Preclinical trials in Sjogren's syndrome in USA (unspecified route)